Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zila divests Zilactin

This article was originally published in The Tan Sheet

Executive Summary

Phoenix-based company sells its Zilactin brand of OTC lip and oral care products to Columbus, Ind.-based Blairex Laboratories for $10.3 mil. "plus agreed upon working capital adjustments," Zila announces June 27. The line includes Zilactin and Zilactin-B (benzocaine), both marketed for the treatment of cold sores, canker sores and fever blisters. The divestiture of the "non-strategic asset" is in line with Zila's plan to focus on "preventive healthcare technologies" such as its Ester-C and Ester-E supplement lines, according to the firm...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel